News | December 25, 2007

Technetium 99-99m Shortage Impacts Cardiac Imaging

December 26, 2007 - The loss of more than 50 percent of the North American Mo-99 supply is now having an impact on the ability of physicians to perform diagnostic cardiac nuclear medicine studies which depend on a reliable daily supply of isotope Technetium (Tc-99m).

Severe cutbacks are occurring throughout the nuclear cardiology community as unit doses of Tc-99m cardiac imaging radiopharmaceuticals are rationed. Urgent nuclear cardiology studies may still be performed with a different cyclotron produced radiopharmaceutical, Thallium-201 (Thallous Chloride).
For non-cardiac imaging with nuclear medicine materials, which includes tests for cancer and other disorders, there are very few practical alternatives to Tc-99m radiopharmaceuticals. Other radiology imaging modalities have limited capability and capacity to fill the void.

Radiologists are making every effort to employ alternative imaging methods to provide the information needed by patients and their primary physicians until the supply issue can be resolved.
Mallinckrodt Medical, a subsidiary of Covidien, is able to secure Mo-99 from its production facility in the Netherlands. However, Mallinckrodt cannot fully replace the Mo-99 deficit with its European source.

The American College of Radiology is investigating how it may be of service to radiologists and other nuclear medicine providers regarding this issue. The College will continue to monitor this situation and will inform members of any developments as information becomes available.

Source: American College of Radiology

For more information: www.acr.org

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init